Nectin Therapeutics: Funding, Investors & Team (Sep 2026)
Nectin Therapeutics is creating new monoclonal antibodies that target the Nectin family of receptors and ligands, which play important roles in the immune checkpoint mechanisms involved in cancer immunotherapy. These antibodies are being developed to treat both solid tumors and blood cancers.
Nectin Therapeutics has raised $10.0M across 1 funding round on record, the most recent an undisclosed round of $10.0M announced in May 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nectin Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2024.
Nectin Therapeutics Funding Rounds
Nectin Therapeutics Founders and Leadership Team
Contact details for the Nectin Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Nectin Therapeutics Funding Compared to Other Biotechnology Startups
Nectin Therapeutics' latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nectin Therapeutics in Biotechnology and Jerusalem
Companies Similar to Nectin Therapeutics
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
Nectin Therapeutics Funding FAQs
What does Nectin Therapeutics do?
Nectin Therapeutics is creating new monoclonal antibodies that target the Nectin family of receptors and ligands, which play important roles in the immune checkpoint mechanisms involved in cancer immunotherapy. These antibodies are being developed to treat both solid tumors and blood cancers.
How much funding has Nectin Therapeutics raised?
Nectin Therapeutics has raised $10.0M across 1 round on record. The most recent is an undisclosed round of $10.0M announced in May 2024.
When did Nectin Therapeutics last raise funding?
Nectin Therapeutics' most recent funding round on record is an undisclosed round of $10.0M, announced in May 2024.
Who founded Nectin Therapeutics?
FundedIQ lists Pini Tsukerman (Founder) at Nectin Therapeutics.
Where is Nectin Therapeutics headquartered?
Nectin Therapeutics is based in Jerusalem, Yerushalayim, Israel.
How many employees does Nectin Therapeutics have?
Nectin Therapeutics is in the 11-50 employee band.
How does Nectin Therapeutics' funding compare to other Biotechnology startups?
Nectin Therapeutics' latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nectin Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nectin Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.